Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. - Wikidata - wikimedia - TriplyDB

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

http://www.wikidata.org/entity/Q37590299

about

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria, Australia.Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting COST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Costs associated with febrile neutropenia in the US.Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.Management of infection and febrile neutropenia in patients with solid cancer.Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.

P2860

Q30977332-3D79CA29-8B44-41FB-AF00-32D346AA1745 Q34677539-EB163097-5487-4804-BF1B-216A0A203A95 Q35730160-01A9FC68-DE53-4161-B026-0175F71555C8 Q36102853-8F90E155-865F-48B4-B8A1-DF1ADBC4EC02 Q36741541-796B56FE-C573-437C-87F3-AA7CC12179C2 Q36853019-889FE478-093A-4A10-B247-A8303F174497 Q36942871-54DEDDEB-E3D9-4081-9C29-22FE2F79424D Q37330372-44CFDB51-296A-48C2-A291-F68F5A373528 Q37554901-5F92F9B5-75C1-47A8-8245-49ACE8E3E99E Q38256944-EB9FC203-13FF-498C-BA05-5A245029C41E Q38689201-274B12A2-254D-4121-A44E-66C5CC2CE7DB Q38823135-43E62077-280D-47D4-A83D-E3FB9DEEFFD2 Q39779938-AE0D4266-3F80-4380-9DAA-C22848C63D5E Q40206253-06E006AE-1EE3-4A30-B3DB-CB63355DADA2 Q40280346-64893114-A19A-473D-AFFD-9137D09FB41C Q40324761-A82A093F-BCCE-478A-BB8F-4FE44FF191BD Q40906626-87F7E76B-6E12-4DFD-AFDC-535CED3E7579 Q43571500-89D51EF9-73D2-4AB9-A6B0-D0D7A68080F5 Q44711105-827EB5B6-C1BE-4CD9-A248-1B5D81847F00 Q46039744-05724F27-D58E-45DD-8053-FF24918B1DB4 Q47376469-68B068DA-23C5-4CEC-9783-14395A298629 Q48537667-71E1C80F-3EA6-4E93-8F2E-F65F4D61D6AE

P2860

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

http://www.wikidata.org/entity/Q37590299

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Retrospective cost analysis of ...... a in cancer patients in Spain.

@en

Retrospective cost analysis of ...... a in cancer patients in Spain.

@nl

type

label

Retrospective cost analysis of ...... a in cancer patients in Spain.

@en

Retrospective cost analysis of ...... a in cancer patients in Spain.

@nl

prefLabel

Retrospective cost analysis of ...... a in cancer patients in Spain.

@en

Retrospective cost analysis of ...... a in cancer patients in Spain.

@nl

P1433

Q37590299-2A493C6A-3124-4EDE-8A11-E5A02E4325E7

P1476

Q37590299-CD55CFF5-F1E1-4B64-8F00-5503862584F2

P2093

Q37590299-1CAD0C22-5323-4710-B473-AA6C59A8899A

Q37590299-333796A4-113B-4ADF-85C4-AC4C9CB7395F

Q37590299-353CF0A1-7F5F-4E76-96C8-CD73707DB215

Q37590299-48D90901-4F25-480E-892E-EC1A59158BFD

Q37590299-55297567-63DA-490C-945B-91F2339EBA27

Q37590299-55DDB4EE-9082-41B0-89C2-269A62D18606

Q37590299-9DEED0D7-1D15-4163-9C78-7ADC78A44CE7

Q37590299-CBE06A28-A200-4487-9B0F-91A03E74EEEC

Q37590299-D6B0DDC1-D50D-4FCE-9456-3530AA57F26E

Q37590299-E0C5F468-46CC-4D0C-9DC1-F65EB9F016FC

P304

Q37590299-11DA66A2-1C72-4E11-AD31-CBB18A77E082

P31

Q37590299-9CE0A8E2-191E-4B96-9FA0-BBFD4D0C474F

P356

Q37590299-5FA54B65-1055-4356-9752-A2A009898EE4

P407

Q37590299-A2412128-6718-48D6-8FE5-025B56AD8550

P433

Q37590299-B8ABD569-F3C3-4F01-9F14-34DD7A089372

P478

Q37590299-50466F8B-8B23-4E4E-9876-CB5B320D565E

P577

Q37590299-E8876A77-822B-4667-82E9-1744FD28488C

P698

Q37590299-56DB81FC-473A-4FF0-8837-822B5E16C6CF

P356

03007990903209563

P1433

Current Medical Research and Opinion

P1476

Retrospective cost analysis of ...... a in cancer patients in Spain.

@en

P2093

Adolfo Frau

http://www.w3.org/2001/XMLSchema#string

Andrés López

http://www.w3.org/2001/XMLSchema#string

ENIA Study Group

http://www.w3.org/2001/XMLSchema#string

Javier Castellanos

http://www.w3.org/2001/XMLSchema#string

Jordi Sánchez

http://www.w3.org/2001/XMLSchema#string

José Antonio Gasquet

http://www.w3.org/2001/XMLSchema#string

José Ignacio Mayordomo

http://www.w3.org/2001/XMLSchema#string

Juan Domingo Alonso

http://www.w3.org/2001/XMLSchema#string

Miquel Layola

http://www.w3.org/2001/XMLSchema#string

Núria Viñolas

http://www.w3.org/2001/XMLSchema#string

P304

2533-2542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1185/03007990903209563

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19722781

http://www.w3.org/2001/XMLSchema#string